Immunosuppression with Generics in Liver and Kidney Transplantation: A Real-World Evidence Study.

Marco FinocchiettiMaria Lucia MarinoAlessandro C RosaArianna Bellini Lucia MasieroMassimo CardilloMarco Massari Stefania Spila-Alegiani Silvia Pierobon Eliana FerroniMartina ZanforliniOlivia LeoniStefano LeddaDonatella GarauMarina DavoliAntonio Addis Valeria Belleudinull null

Published in: Drug design, development and therapy (2024)

The study shows an increasing proportion of patients using generic immunosuppressive drugs over time suggesting a growing acceptance of generics within the transplant community and reveals comparable risk-benefit profiles between the generic and branded formulations of TAC, CsA, and MYC. A significant variability in the use of generics immunosuppressive agents was found both at the regional level and among transplant centers and future research should delve into regional prescribing variations.

Keyphrases

kidney transplantation
end stage renal disease
primary care
chronic kidney disease
newly diagnosed
ejection fraction
mental health
emergency department
transcription factor
patient reported outcomes